Cost Disparities with Age in the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) in Ontario, Canada
Current Oncology · 2025
DOI: 10.3390/curroncol32060346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Ying Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, BC Cancer Vancouver, University of British Columbia; Vancouver, BC V5Z 4E6, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Health Care Costs. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Ontario Cancer Data Linkage Program (“cd-link”).
Abstract (Originalsprache)
Previous studies have noted associations between age and healthcare costs in non-small-cell lung cancer (NSCLC). However, the drivers of cost disparities have not yet been fully examined. This retrospective cohort study included deceased patients diagnosed with stage IV NSCLC in Ontario from 1 April 2008 to 30 March 2014. Variables of interest were extracted from the Institute for Clinical Evaluative Sciences. Average monthly cancer-attributable costs (CACs), defined as the net additional costs due to cancer, determined by subtracting pre-diagnosis costs from post-diagnosis costs, were calculated by phases of care (staging, initial, continuing, and end-of-life). Regression analyses assessed predictors of cost variability. The median age of the 14,655 patients was 65 to 69 years; 54% were male and 29% had received chemotherapy. On both univariate and multivariate analysis, CACs decreased with age after cancer diagnosis across all phases of care (p < 0.001). Receiving chemotherapy contributed to higher costs in staging, initial, and continuing phases (OR 2.11, 95% C.I. 1.90–2.33, p < 0.01), and lower costs in the end-of-life phase (OR 0.77, 95% C.I. 0.72–0.81, p < 0.01). Our study showed that older patients had higher baseline healthcare costs and lower cancer-attributable costs following diagnosis of advanced NSCLC. Cost drivers, including treatment and gender, varied by phase of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, BC Cancer Vancouver, University of British Columbia; Vancouver, BC V5Z 4E6, Canada.
- Ontario Clinical Oncology Group, Department of Oncology, Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON L8V 1C3, Canada.
- Department of Health Research Methods, Evidence and Impact, Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, ON L8S 4L8, Canada.
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Department of Oncology, Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON L8V 1C3, Canada.
ORCID-Profile: Ying Wang, Greg Pond, Peter M Ellis
Förderung
- the Ontario Cancer Data Linkage Program (“cd-link”)
Zitieren
APA
Wang, Y., Pond, G., Gafni, A. J., Kong, C. Y., & Ellis, P. M. (2025). Cost Disparities with Age in the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) in Ontario, Canada. Current Oncology. https://doi.org/10.3390/curroncol32060346
Vancouver
Wang Y, Pond G, Gafni AJ, Kong CY, Ellis PM. Cost Disparities with Age in the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) in Ontario, Canada. Current Oncology. 2025. doi:10.3390/curroncol32060346
BibTeX
@article{Wang2025,
author = {Wang, Ying and Pond, Greg and Gafni, Amiram Jacob and Kong, Chung Yin and Ellis, Peter M},
title = {Cost Disparities with Age in the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) in Ontario, Canada},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32060346}
}
EUVIMED